Camidanlumab tesirine

DB16411InvestigationalProtein Based Therapies

Camidanlumab tesirine is under investigation in clinical trial NCT04639024 (ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN).

Mechanism
Curator reviewed
Code names
ADCT-301 · ADCT 502

Resolves to

Compound
UNIILYJ1AEJ9YHCAS1853239-04-9
Targets
P01589IL2RA

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Camidanlumab tesirine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In